Latest News

Kamada Reports Financial Results for Fourth Quarter and Full-Year 2017

Feb. 7, 2018

Kamada Reports Financial Results for Fourth Quarter and Full-Year 2017.

Kamada Announces Interim Results from Phase 2 Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection

Jan. 8, 2018

The company announced interim results from the Company’s Phase 2 trial of intravenous Alpha-1 Antitrypsin (IV AAT) for the prevention of lung transplant rejection.

Upcoming Events

Kamada to participate in Oppenheimer's 28th Annual Healthcare Conference (OPCO)

Mar. 20-21, 2018 / New-York City, USA

At this conference, investors will be presented with a broad spectrum of public and private companies who are leaders and pioneers in the biopharmaceutical, biotechnology, medical device, life science tools & diagnostics, health technology & distribution, and healthcare facility, provider, and service industries.

Kamada to participate in H. C. Wainwright Global Biotechnology Conference

Apr. 8-10, 2018 / Monte Carlo, Monaco

H.C. Wainwright & Co. is one of the country’s oldest and leading financial institutions. Their  services are tailored to meet the clients’ needs and their expertise spans a wide range of industries and organizations. They are devoted to building long-term relationships with clients and find that many of the clients seek their services on a repeated basis.

Past Event

Kamada to participate in EBMT Annual Meeting 2018

Mar. 18-21, 2018 / Lisbon, Portugal

The EBMT Annual Meeting is the Society’s flagship event. It brings together scientists, physicians, nurses, data managers, patients, quality managers, statisticians, pharmacists, biologists, technicians and psychologists from Europe and all over the world. The exciting scientific programme is designed to cover the key issues relating to hematopoleic stem cell transplantation and cellular therapy research.